Update Teva Pharmaceutical Industries (TEVA)
posted on June 4, 2010 at 3:05 pm
A busy month for drug announcements at Teva Pharmaceutical Industries (TEVA) with news on Copaxone, Azilect, and Gianvi–and it’s only June 4.
Of these Gianvi is the biggie—at least for now.
The drug is a generic version of Bayer’s (BAYRY) oral contraceptive Yaz. Sales of Yaz came to $780 million in 2009. The contraceptive has been especially popular among younger women since taking it produces less water retention than some other contraceptives and works to reduce acne. But sales of Yaz have dropped recently to an annual rate of about $600 million as Bayer has cut back on advertising and promotion. (Bayer’s newest contraceptive Natazia was approved for sale in May.)
The Gianvi launch counts as a positive surprise for Teva. Read more
